Torrent Pharmaceuticals (TORNTPHARM.NS) Osake Kurssi
Torrent Pharmaceuticals Kurssi
Viimeisten 19 vuoden aikana Torrent Pharmaceuticalsn liikevaihto kasvoi 13,3 % vuodessa ja ylsi 139,80 Mrd. INR:een. Osakekohtainen tulos on kasvanut 18,0 % vuodessa viimeisten 19 vuoden aikana. Torrent Pharmaceuticalsn nettomarginaali 15,5 % on noussut verrattuna 9,2 %:iin muutama vuosi sitten. Nykyhinnalla osinkotuotto on noin 0,74 %. Jakosuhde on noin 58 % tuloksesta. Osinko on kasvanut 22,4 % vuodessa viimeisten 19 vuoden aikana. Torrent Pharmaceuticalsn 12 kuukauden konsensustavoitehinta on 4 166,70 INR, noin ali kurssia 12,1 %. 33 analyytikosta 23 suosittaa ostoa — kokonaiskonsensus on Osta.
Torrent Pharmaceuticals osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Torrent Pharmaceuticals liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Torrent Pharmaceuticals -osakkeesta
The business model of Torrent Pharmaceuticals Ltd involves the research, development, production, and marketing of high-quality generic pharmaceuticals and active pharmaceutical ingredients (APIs). As one of the leading players in the Indian pharmaceutical industry, Torrent Pharmaceuticals focuses on delivering affordable and accessible healthcare solutions to a wide range of patients. Their business strategy entails a strong emphasis on product quality, regulatory compliance, and timely introduction of new products. Torrent Pharmaceuticals aims to address various therapeutic segments, including cardiology, diabetology, gastroenterology, and pain management, through a robust portfolio of formulations. The company strives to enhance its global footprint and maintain a strong market position through continuous innovation and strategic partnerships.
Torrent Pharmaceuticals Ltd is primarily active in the pharmaceutical industry.
Torrent Pharmaceuticals Ltd has several main competitors in the market. Some of the prominent competitors of Torrent Pharmaceuticals Ltd include Sun Pharmaceutical Industries Ltd, Lupin Limited, Cipla Ltd, Dr. Reddy's Laboratories Ltd, and Aurobindo Pharma Ltd. These companies operate in the same industry and offer similar products and services, leading to competition in the market. However, with its strong market presence and diverse product portfolio, Torrent Pharmaceuticals Ltd continues to strive and maintain its position among the top competitors.
Torrent Pharmaceuticals Ltd is a reputed pharmaceutical company with a rich history and background. Established in 1959, Torrent Pharmaceuticals has emerged as one of India's leading pharmaceutical companies. With a diverse product portfolio spanning therapeutic areas like cardiovascular, central nervous system, and gastroenterology, the company has made significant contributions to healthcare. Torrent Pharmaceuticals is committed to quality, innovation, and patient-centricity, driving its growth within India and globally. Over the years, the company has garnered recognition for its research and development capabilities, extensive manufacturing infrastructure, and strong ethical practices, making it a trusted player in the pharmaceutical industry.
Torrent Pharmaceuticals Ltd has achieved several significant milestones in its journey. The company has successfully expanded its global presence, entering new markets and launching various products. It has received multiple regulatory approvals for its quality-driven manufacturing facilities, ensuring compliance with international standards. Torrent Pharmaceuticals Ltd has been recognized for its commitment to research and development, developing innovative healthcare solutions and improving patient outcomes. The company has also demonstrated strong financial performance, consistently delivering sustainable growth and creating value for its stakeholders. With its dedication to excellence and continuous improvement, Torrent Pharmaceuticals Ltd continues to make remarkable strides in the pharmaceutical industry.
Torrent Pharmaceuticals Ltd is primarily present in multiple countries and regions. The company has a strong global presence and operates in several key markets such as India, the United States, Brazil, Germany, Spain, Russia, and many more. With its diverse geographic footprint, Torrent Pharmaceuticals Ltd has established a wide customer base and significant market reach. The company's global expansion helps facilitate access to its products and allows it to cater to the healthcare needs of various populations around the world.
Torrent Pharmaceuticals Ltd represents values of excellence, integrity, and commitment in the pharmaceutical industry. As one of the largest pharmaceutical companies in India, Torrent Pharmaceuticals is dedicated to providing high-quality and affordable healthcare solutions to patients worldwide. The company's corporate philosophy revolves around innovation, ethical practices, and customer-centricity, ensuring the delivery of safe and effective medicines. With a strong emphasis on research and development, Torrent Pharmaceuticals strives to contribute to the well-being of society by constantly expanding its product portfolio and enhancing healthcare access.
Analyytikot asettavat tällä hetkellä Torrent Pharmaceuticals-osakkeelle keskimääräisen tavoitehinnan 4 140,77 INR (mediaani: 4 166,70 INR), mikä merkitsee −12,6 % viimeisimpään hintaan verrattuna. Konsensus perustuu 33 analyytikkoarvioon.
33 analyytikkoa arvioi tällä hetkellä Torrent Pharmaceuticals-osaketta: 23 suosittaa ostoa, 8 pitoa ja 2 myyntiä.
Nykyisellä valuuttakurssilla Torrent Pharmaceuticals-osake noteerataan hintaan 45,55 EUR (4 738,00 INR).
Torrent Pharmaceuticals-osake (TORNTPHARM.NS) on listattuna 2 pörssissä, muun muassa: NSE (Indien) (TORNTPHARM.NS).
Torrent Pharmaceuticals Ltd is an Indian pharmaceutical company founded in 1959. It focuses on the manufacturing and distribution of pharmaceuticals and operates in various areas including generics, over-the-counter products, active pharmaceutical ingredients, and bio-pharmacology. The company is known for its cost-effective alternatives to branded drugs and has a strong presence in the Indian and global markets. It specializes in generics, over-the-counter products, active pharmaceutical ingredients, and bio-pharmacology. It has a wide range of products in its portfolio, including anti-infectives, cardiovascular drugs, CNS drugs, gastrointestinal drugs, painkillers, and OTC products. Torrent Pharmaceuticals has a reputation as a leading generic manufacturer in India.
liikevaihto Torrent Pharmaceuticals on 139,80 Mrd. INR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
voitto Torrent Pharmaceuticals on 21,63 Mrd. INR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Torrent Pharmaceuticals:n hinta-voitto-suhde (P/E) on tällä hetkellä 83,25. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Torrent Pharmaceuticals-osakkeen arvostusta.
Torrent Pharmaceuticals:n hinta-myynti-suhde (P/S) on tällä hetkellä 12,88. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Torrent Pharmaceuticals-osakkeen arvostuskennuslukuna.
Torrent Pharmaceuticals:n Eulpool-laatuscore on 6/10.
Torrent Pharmaceuticals:n ISIN on INE685A01028. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Torrent Pharmaceuticals:n ticker on TORNTPHARM.NS. Tämä pörssinoteeraus käytetään Torrent Pharmaceuticals-osakkeiden kauppaan pörssissä.
Torrent Pharmaceuticals osake
Torrent Pharmaceuticals vertaisryhmä
Torrent Pharmaceuticals Ticker
Torrent Pharmaceuticals FIGI
Kaikki tunnusluvut ja syvällinen analyysi Torrent Pharmaceuticals:sta
Meidän osakeanalyysimme Torrent Pharmaceuticals-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Torrent Pharmaceuticals:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: